Search results for "ATHEROSCLEROSIS"

showing 10 items of 499 documents

Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.

2006

Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atherosclerotic disease alongside coronary heart disease (CHD) and cerebrovascular disease (CVD). Best medical treatment is beneficial even in patients who eventually need invasive treatment, as the safety, immediate success, and durability of intervention is greatly improved in patients who adhere to best medical treatment. In recent years, a number of studies have suggested that the ACE-inhibitor ramipril and different statins, together with antiplatelet drugs, reduce cardiovascular morbidity and mortality in PAD. Patients with PAD are really a category of patients with a very high cardiovascular risk…

Ramiprilmedicine.medical_specialtyRenal functionCoronary Diseasechemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesPeripheral Vascular DiseasesFramingham Risk ScoreCholesterolbusiness.industryAnticholesteremic AgentsGeneral MedicineArteriesCholesterol LDLIntermittent ClaudicationAtherosclerosisIntermittent claudicationPeripheralchemistryHemostasisCardiologyDisease Progressionmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsClaudicationbusinessmedicine.drugArchives of medical research
researchProduct

trans -Lycopene from tomato juice attenuates inflammatory biomarkers in human plasma samples: An intervention trial

2017

cope : To evaluate the effects of carotenoids from tomato juice (TJ) on inflammatory biomarkers, by performing a 4-week dose-response nutritional trial in a population at high cardiovascular risk. Methods and results : An open, prospective, randomized, cross-over, and controlledclinical trial was carried out with 28 volunteers (mean age 69.7 ± 3.1 years; mean BMI 31.5 ± 3.6 kg/m2) at high cardiovascular risk, which were assigned to consume daily for 4 weeks in random order: 200 mL (LD) or 400 mL (HD) of TJ, or water as a control (C), with a 21-day wash-out period between each intervention. Blood samples were collected at baseline (B) and after each intervention. Endpoints included significa…

Risk0301 basic medicinemedicine.medical_specialtyChemokinePopulationVascular Cell Adhesion Molecule-1Inflammation030204 cardiovascular system & hematologyGastroenterologyBody Mass Index03 medical and health scienceschemistry.chemical_compoundLycopene0302 clinical medicineSolanum lycopersicumFunctional FoodInternal medicinemedicineHumansObesityIntervention trialeducationCarotenoidAgedchemistry.chemical_classificationeducation.field_of_studyCross-Over Studies030109 nutrition & dieteticsbiologyAnti-Inflammatory Agents Non-SteroidalStereoisomerismMiddle AgedAtherosclerosisIntercellular Adhesion Molecule-1CarotenoidsInflammatory biomarkersLycopeneSurgeryFruit and Vegetable JuiceschemistrySpainHuman plasmabiology.proteinInflammation Mediatorsmedicine.symptomBiomarkersFollow-Up StudiesFood ScienceBiotechnologyMolecular Nutrition & Food Research
researchProduct

Oxidative stress in cardiovascular disease: successful translation from bench to bedside?

2007

Over the last decades, sound evidence has been generated that oxidative stress is one of the most potent inductors of endothelial dysfunction and is involved at all stages of atherosclerotic plaque evolution.1,2 Experimental and animal models provide a clear association between the amount of oxidative challenge and reversible vascular dysfunction that can be observed before permanent alterations of the vessel wall occur. Article p 1367 Important for cardiovascular biology is the consumption of nitric oxide (NO) by reactive oxygen species. Endothelium relaxant factor is a central molecule in vascular homeostasis as a modulator of endothelial tone and reactivity.3 It is produced by NO synthas…

RiskEndotheliumOxidative phosphorylation030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeArginineNitric OxideNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)medicineHumansEndothelial dysfunction030304 developmental biologychemistry.chemical_classification0303 health sciencesReactive oxygen speciesbiologybusiness.industryThrombosismedicine.diseaseAtherosclerosis3. Good healthVasodilationOxidative Stressmedicine.anatomical_structurechemistryCardiovascular DiseasesMyeloperoxidaseImmunologyHemorheologybiology.proteinEndothelium VascularCardiology and Cardiovascular MedicinebusinessReactive Oxygen SpeciesPeroxynitriteOxidative stressBiomarkersCirculation
researchProduct

Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2)

2011

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a calcium-independent phospholipase A2 that circulates in plasma in association with lipoprotein particles, whereas in atherosclerotic plaques it is co-localized with macrophages. Lp-PLA2 generates two proinflammatory mediators, lysophosphatidylcholine and oxidized nonesterified fatty acids, which play a role in the development of atherosclerotic lesions and formation of a necrotic core, leading to more vulnerable plaques. Epidemiologic studies demonstrate that increased circulating levels of Lp-PLA2 predict an increased risk of myocardial infarction, stroke and cardiovascular mortality. Furthermore, histologic examination of diseased hum…

RiskPathologymedicine.medical_specialtycoronary-artery-diseasecardiovascular-diseasePharmacologyatherosclerotic plaqueProinflammatory cytokinechemistry.chemical_compoundPhospholipase A2cardiovascular diseaseDarapladibOximesDrug DiscoveryHyperlipidemiamedicineHumansMyocardial infarctionPharmacologyClinical Trials as Topicbiologylow-density-lipoproteinLipoprotein-associated phospholipase A2risk-assessmentCardiovascular AgentsAtherosclerosismedicine.diseaselp-pla2heart-diseaselipoproteinsLysophosphatidylcholinechemistryCardiovascular DiseasesinflammationBenzaldehydes1-Alkyl-2-acetylglycerophosphocholine Esterasebiology.proteindarapladibrheumatoid-arthritislipids (amino acids peptides and proteins)atherosclerosisfactor-acetylhydrolase activityAtherosclerosis Cardiovascular disease Darapladib Inflammation Lipoproteins Lp-PLA2.platelet-activating-factorsecondary preventionLipoprotein
researchProduct

Heat Shock Protein-60 and Risk for Cardiovascular Disease

2011

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. There is growing evidence that molecularchaperones, many of which are heat shock proteins HSPs, are involved in CVD pathogenesis. In this review we focus on HSP60,the human mitochondrial chaperone that also displays extramitochondrial and extracellular functions. HSP60 is typically cytoprotectivebut a number of stress conditions determine its conversion to a potentially toxic molecule for cells and tissues. We present illustrative examplesof specific subtypes of CVD where HSP60 is implicated in the initiation and/or progression of disease. The data not only indicatea pathogenic role for HSP60 but also its …

Riskanimal structuresChaperonin Heat shock protein-60 cardiomyocytes heart failure cardiovascular diseases atherosclerosisChaperonin heat shock protein 60 cardiomyocytes heart failure cardiovascular disease atherosclerosis apoptosis microRNAs (miRs) diabetes Atrial fibrillationApoptosischemical and pharmacologic phenomenaDiseaseBioinformaticsAutoimmune DiseasesPathogenesisHeat shock proteinAtrial FibrillationDrug DiscoveryExtracellularAnimalsHumansMyocytes CardiacHeart FailurePharmacologybiologyfungiChaperonin 60AtherosclerosisResponse to treatmentCardiovascular DiseasesReperfusion InjuryChaperone (protein)HypertensionImmunologybiology.proteinHSP60Stress conditionsBiomarkersCurrent Pharmaceutical Design
researchProduct

ST elevāciju miokarda infarkta noteicošās artērijas intravaskulārās ultraskaņas audu raksturojuma saistība ar aterosklerozes asins biomarķieriem un s…

2013

Anotācija ST elevāciju miokarda infarkta gadījumā (STEMI) patofizioloģiskais substrāts ir rupturējusi vai erodējusi panga un tromboze. Šajā darbā veicām iMap IVUS audu analīzi STEMI mērķa bojājumiem 75 pacientiem, noteicām asinīs aterosklerozes biomarķierus un veicām 10 mēnešu apsekojumu. Mūsu rezultāti parādīja augstu nekrotisko audu daudzumu mērķa bojājumā un augstu, bet salīdzinoši zemāku, proksimālajā segmentā. Proksimālajā segmentā 10 mēnešu laikā samazinājās lipīdu audu daudzums par 10,2%. Neointimai 10 mēnešus pēc stenta implantācijas bija raksturīgs stabilāks audu sastāvs pēc iMap IVUS nekā natīvai aterosklerotiskai pangai šajā artērijā. Asins aterosklerozes biomarķieru saistību ar …

STEMIiMap intravaskulārā ultraskaņaaterosklerozes asins biomarķierineoatherosclerosisMedicineneoaterosklerozeMedicīna un farmācijaST elevāciju miokarda infarktsiMap intravascular ultrasoundVeselības aprūpeatherosclerosis blood biomarkersMedicīna
researchProduct

Hsp60 and human aging: Les liaisons dangereuses 

2013

Stressors can cause abnormal intracellular accumulation of Hsp60 and its localization in extramitochondrial sites, secretion, and circulation, with immune system activation. Dysfunction of chaperones associated with their quantitative and qualitative decline with aging (chaperonopathies of aging) characterizes senescence and is a potential causal factor in the physiological deterioration that occurs with it. The role of Hsp60 in aging is not easy to elucidate, because aging is accompanied by pathologies (e.g., cardiovascular and neurodegenerative disorders, osteoporosis, diabetes, cancer, etc.) in which Hsp60 has been implicated but, although those disorders are more frequent in the elderly…

SenescenceAginganimal structuresOsteoporosischemical and pharmacologic phenomenaInflammationDiseaseBiologycomplex mixturesMitochondrial ProteinsPathogenesisImmune systemDiabetes mellitusmedicineHumansCellular SenescenceAutoantibodiesHeart FailurefungiHSP 60 AGING CHAPERONES.Neurodegenerative DiseasesChaperonin 60Atherosclerosismedicine.diseaseMitochondriaImmune SystemImmunologyHSP60Arthropathy Neurogenicmedicine.symptomFrontiers in Bioscience
researchProduct

Atrial natriuretic factor,but non oxytocin, presence in atherosclerotic plaques of human common carotid arteries

2009

Settore BIO/16 - Anatomia UmanaANPOxytocinAtherosclerosisCommon carotid arteries
researchProduct

ANP immunolocalization in internal carotid artery wall of subjects with and without atherosclerotic lesions

2008

Settore BIO/16 - Anatomia UmanaANPatherosclerosis internal carotid artery.
researchProduct

Gli aneurismi dell'aorta addominale

2009

Not available

Settore BIO/17 - IstologiaAbdominal aortic aneurism ACE IL MMPs PAF TIMP-2 atherosclerosis EVARSettore MED/22 - Chirurgia VascolareAneurisma aorta addominale ACE IL MMPs PAF EVAR
researchProduct